Pompe disease (PD) is an autosomal recessive disease caused by partial or complete deficiency of the lysosomal hydrolase acid alpha-glucosidase, resulting in accumulation of glycogen in various tissues. It affects primarily the skeletal, smooth muscle and cardiac system. Pompe disease clinically presents as a continuum in its age of onset and multisystem involvement and is often fatal. Diagnosis can be difficult due to nonspecific phenotype of the disease. Enzyme replacement therapy (ERT) is the standard treatment for the disease since 2006. Although of considerable clinical benefit to some patients, there are significant limitations to ERT. Studies in novel therapeutic approaches show positive outcomes. In the context of therapeutic options, the earliest diagnosis and initiation of treatment can make a difference. Early identification through newborn screening and more effective therapies will hopefully lead to improved outcomes for patients with Pompe Disease.